Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 0.96 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 3/20 | 0.96 |
| ▸ | HTR3B known ✓ | O95264 | 3/20 | 0.96 |
| ▸ | HTR3A known ✓ | P46098 | 3/20 | 0.96 |
| ▸ | HTR3D known ✓ | Q70Z44 | 3/20 | 0.96 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 3/20 | 0.96 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.96 |
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 0.66 |
| ▸ | HTR1B known ✓ | P28222 | 2/20 | 0.66 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.66 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.57 |
| ▸ | HTR7 known ✓ | P34969 | 2/20 | 0.55 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.55 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 4/20 | 0.62 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1724680 | 1.00 | ADRB1 (0.96) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2410870 | 0.98 | ADRB1 (1.00) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL234280 | 0.98 | ADRB1 (1.00) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Bromide SCHEMBL11070661 | 0.96 | ADRB1 (0.96) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Piperazine SCHEMBL8590918 | 0.96 | ADRB1 (0.96) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL7921830 | 0.95 | ADRB1 (0.86) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2881283 | 0.93 | ADRB1 (0.89) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL9058690 | 0.93 | ADRB1 (0.89) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5237992 | 0.91 | ADRB1 (0.86) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7171062 | 0.91 | ADRB1 (0.86) | ADRB1HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200224057-A1 | DUAL ADDITIVE COMPOSITION FOR POLISHING MEMORY HARD DISKS EXHIBITING EDGE ROLL OFF | CABOT MICROELECTRONICS CORPORATION | 2020-07-16 | — | — | US | claimed |
| WO-2020146161-A1 | DUAL ADDITIVE COMPOSITION FOR POLISHING MEMORY HARD DISKS EXHIBITING EDGE ROLL OFF | CABOT MICROELECTRONICS CORPORATION (US) | 2020-07-16 | — | — | WO | claimed |
| US-11384253-B2 | Dual additive composition for polishing memory hard disks exhibiting edge roll off | CMC MATERIALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| WO-2020146161-A1 | DUAL ADDITIVE COMPOSITION FOR POLISHING MEMORY HARD DISKS EXHIBITING EDGE ROLL OFF | CABOT MICROELECTRONICS CORPORATION (US) | 2020-07-16 | — | — | WO | disclosed |
| US-20200224057-A1 | DUAL ADDITIVE COMPOSITION FOR POLISHING MEMORY HARD DISKS EXHIBITING EDGE ROLL OFF | CABOT MICROELECTRONICS CORPORATION | 2020-07-16 | — | — | US | disclosed |
| EP-2350311-B1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | MADRIGAL PHARMACEUTICALS INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-8383631-B2 | 1,6-disubstituted-3-amino-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-C]pyridin-7-one compounds and preparation thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-02-26 | — | — | US | disclosed |
| US-8324385-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110319619-A1 | NOVEL 1,6-DISUBSTITUTED-3-AMINO-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7-ONE COMPOUNDS AND PREPARATION THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-12-29 | — | — | US | disclosed |
| EP-2350311-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010056506-A1 | DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-4267179-A | AS FUNGICIDES AND BACTERICIDES | JANSSEN PHARMACEUTICA, N.V. (BE) | 1981-05-12 | — | — | US | disclosed |
| US-4223036-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-09-16 | — | — | US | disclosed |
| US-4205173-A | 1-Heterocyclic alkyl-1,2,3,4-tetrahydroquinazolinones and analgesic intermediates thereof | PENNWALT CORPORATION (US) | 1980-05-27 | — | — | US | disclosed |
| EP-0007696-A1 | Heterocyclic derivatives of (4-(piperazin-1-yl-phenyloxymethyl)-1.3.-dioxolan-2-ylmethyl)-1H-imidazoles and -1H-1.2.4-triazoles, their preparation and use as fungicides and bactericides | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-02-06 | — | — | EP | disclosed |
| EP-0006711-A1 | Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)-methyl-1H-imidazoles and 1H-1,2,4-triazoles, processes for preparing them and compositions containing them | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-01-09 | — | — | EP | disclosed |
| US-4144346-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-03-13 | — | — | US | disclosed |
| US-4140775-A | HYPOTENSIVE AGENTS | THE UPJOHN COMPANY (US) | 1979-02-20 | — | — | US | disclosed |
| US-4060526-A | 1-Heterocyclic alkyl-1,2,3,4-tetrahydroquinazolinones and analgesic intermediates thereof | PENNWALT CORPORATION (US) | 1977-11-29 | — | — | US | disclosed |
| US-3947447-A | CENTRAL NERVOUS SYSTEM DEPRESSANT, ANTICONVULSANT, MUSCLE RELAXANT, HYPOTENSIVE | AMERICAN HOECHST CORPORATION (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319619-A1 | NOVEL 1,6-DISUBSTITUTED-3-AMINO-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7-ONE COMPOUNDS AND PREPARATION THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, THPO, PLEC | ADRB1 2359/4885HTR3E 1091/4885HTR3B 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.